Skip to main content
    A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.10
    +2.69 (+10.19%)

    Market Cap: $3.32B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(22/28)
    Avg Surprise
    +16.48%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.17
    Range$0.14 - $0.20
    5 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.08+126.3%
    60d ago$0.08+119.7%
    30d ago$0.16+8.7%
    7d ago$0.16+8.7%
    Current$0.17
    Revenue Consensus
    $142M
    Range$140M - $146M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.27
    Range$0.04 - $0.46
    5 analysts
    Revenue Consensus
    $173M
    Range$165M - $184M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.27---
    Sep 26EST
    		-$0.17---
    Jun 26
    Reported Aug 5
    		$0.11$0.09+22.22%Beat+184.6%
    Mar 26
    Reported May 6
    		$-0.09$-0.06-50.00%Miss+55.0%
    Dec 25
    Reported Feb 25
    		$0.13$0.09+46.73%Beat+244.4%
    Sep 25
    Reported Oct 28
    		$0.06$-0.09+166.67%Beat+118.2%
    Jun 25
    Reported Aug 6
    		$-0.13$-0.16+18.75%Beat+69.0%
    Mar 25
    Reported May 6
    		$-0.20$-0.21+4.76%Beat+37.5%
    Dec 24
    Reported Feb 25
    		$-0.09N/A+65.95%Beat+87.5%
    Sep 24
    Reported Nov 6
    		$-0.33$-0.42+21.43%Beat+54.8%
    Jun 24
    Reported Aug 14
    		$-0.42$-0.53+20.75%Beat+63.8%
    Mar 24
    Reported May 14
    		$-0.32N/A+56.16%Beat+75.6%
    Dec 23
    Reported Feb 27
    		$-0.72$-0.80+10.00%Beat+39.0%
    Sep 23
    Reported Nov 3
    		$-0.73$-0.91+19.78%Beat+61.4%
    Jun 23
    Reported Aug 8
    		$-1.16$-1.25+7.20%Beat+11.5%
    Mar 23
    Reported May 9
    		$-1.31$-1.26-3.97%Miss-3.1%
    Dec 22
    Reported Feb 28
    		$-1.18$-1.42+16.90%Beat+16.9%
    Sep 22
    Reported Nov 8
    		$-1.89$-1.75-8.00%Miss-65.8%
    Jun 22
    Reported Aug 4
    		$-1.31$-1.42+7.75%Beat-56.0%
    Mar 22
    Reported May 5
    		$-1.27$-1.52+16.45%Beat-67.1%
    Dec 21
    Reported Feb 22
    		$-1.42$-1.49+4.70%Beat-79.7%
    Sep 21
    Reported Nov 4
    		$-1.14$-1.19+4.20%Beat-12.9%
    Jun 21
    Reported Aug 5
    		$-0.84$-0.93+9.68%Beat+10.6%
    Mar 21
    Reported May 4
    		$-0.76$-0.97+21.65%Beat+33.9%
    Dec 20
    Reported Feb 16
    		$-0.79$-0.86+8.14%Beat+87.2%
    Sep 20
    Reported Nov 5
    		$-1.01$-0.90-12.22%Miss+86.7%
    Jun 20
    Reported Aug 11
    		$-0.94$-0.84-11.90%Miss-452.9%
    Mar 20
    Reported May 12
    		$-1.15$-0.85-35.29%Miss-
    Dec 19
    Reported Jan 31
    		$-6.18$-9.21+32.90%Beat-
    Sep 19
    Reported Nov 27
    		$-7.60$-7.60+0.00%Beat-
    Jun 19
    Reported Sep 9
    		$-0.17$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio138.57EV/EBITDA124.94x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin6.15%Operating Margin12.70%
    ROE15.90%ROIC8.77%
    Financial Health
    Debt/Equity0.49xInterest Coverage2.14x
    Current Ratio2.92xQuick Ratio2.67x
    Trading Statistics
    Beta1.58Avg Volume3.33M
    52-Week High$31.7752-Week Low$19.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$25.73
    SMA 20$26.09
    SMA 50$25.43
    SMA 200$25.07
    EMA 10$26.38
    EMA 20$25.98
    EMA 50$25.69
    EMA 200$24.50

    MACD

    Line: 0.39Signal: 0.13Hist: 0.26

    ADX

    ADX: 19.6+DI: 36.0-DI: 15.8

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down12.0
    PSAR$23.65

    Bollinger Bands

    Upper Band$28.56
    Lower Band$23.62
    %B Position1895%(Upper)
    Band Width1.11

    RSI (14-Day)

    Neutral
    66.3

    Momentum Oscillators

    Stoch %K76.4
    Stoch %D68.4
    Williams %R-5.9
    ROC (10d)15.1%
    Momentum3.81
    CCI (20d)194.3
    MFI (14d)46.5

    Volatility Measures

    ATR (14d)$1.36(4.7%)
    StdDev (20d)1.24
    Hist Vol66.2%(High)

    Volume Flow

    VWAP$28.50
    OBV32.7M
    AD Line12.1M
    CMF (20d)-0.165

    Volume Metrics

    Avg Vol (20d)3.1M
    Vol Ratio1.2x
    VWMA (20d)$26.01

    Pivot Points

    R3$28.03
    R2$27.48
    R1$26.95
    Pivot Point$26.40
    S1$25.87
    S2$25.32
    S3$24.79

    Advanced Oscillators

    TSI8.15
    Ultimate Osc66.8
    KST31.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$129.86M$105.40M$129.50M$99.22M$81.50M$65.85M$71.36M$44.76M$30.86M$49.57M$13.53M$38.11M
    Cost of Revenue$10.94M$9.78M$11.69M$8.69M$7.49M$8.83M$6.91M$5.50M$3.46M$3.26M$2.25M$1.18M
    Gross Profit$118.92M$95.61M$117.81M$90.53M$74.01M$57.02M$64.45M$39.25M$27.39M$46.31M$11.28M$36.93M
    Operating Expenses$102.49M$104.70M$99.43M$82.01M$88.62M$81.55M$72.09M$78.32M$77.47M$77.94M$72.45M$73.83M
    R&D$20.36M$30.63M$20.45M$19.60M$19.45M$17.54M$14.48M$19.50M$19.30M$23.14M$23.77M$26.24M
    SG&A$82.14M$74.08M$78.98M$62.40M$69.17M$64.00M$57.61M$58.82M$58.17M$54.79M$48.67M$47.59M
    Operating Income$16.43M$-9,089,000$18.39M$8.53M$-14,611,000$-24,529,000$-7,632,000$-39,066,000$-50,077,000$-31,622,000$-61,169,000$-36,904,000
    Interest Income$2.28M$2.27M$0$0$2.08M$2.54M$0$0$0$0$0$0
    Interest Expense$3.41M$4.37M$3.00M$3.07M$3.03M$2.98M$5.55M$6.65M$7.48M$7.48M$7.76M$7.56M
    Income Before Tax$15.14M$-11,202,000$17.86M$7.49M$-15,544,000$-24,781,000$-10,465,000$-41,537,000$-52,332,000$-35,058,000$-66,194,000$-41,742,000
    Income Tax Expense$136,000$93,000$470,000$80,000$342,000$279,000$323,000$0$0$324,000$90,000$3.02M
    Net Income$15.01M$-11,295,000$17.39M$7.41M$-15,886,000$-25,060,000$-10,788,000$-41,537,000$-52,332,000$-35,382,000$-66,284,000$-44,765,000
    EBITDA$16.61M$-8,729,000$12.54M$10.57M$-14,723,000$-22,216,000$-21,823,000$-35,305,000$-47,049,000$-28,945,000$-72,234,000$-35,328,000
    EBIT$16.27M$-9,109,000$11.97M$10.56M$-14,591,000$-24,336,000$-21,040,000$-34,884,000$-44,848,000$-27,578,000$-70,949,000$-34,183,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARQT

    News

    Form 144 Arcutis Biotherapeutics For: 16 October By Investing.com

    This article from Investing.com reports on a Form 144 filing for Arcutis Biotherapeutics, dated October 16. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal detail beyond...

    Investing.com India•10/16/26•Neutral

    (ARQT) Movement as an Input in Quant Signal Sets

    This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) using quantitative signals. It identifies strong near-term sentiment with a neutral mid and long-term outlook...

    Stock Traders Daily•10/15/26•Somewhat-Bullish

    Arcutis CEO Frank Watanabe: Zoryve's $525M Guidance Rests on a Clinician-Led Revolt Against Topical Steroids

    Arcutis Biotherapeutics CEO Frank Watanabe projects Zoryve's substantial revenue guidance on the back of a growing "steroid stewardship" movement, driven by clinicians...

    BigGo Finance•10/13/26•Bullish

    Arcutis Biotherapeutics, Inc. (ARQT) Stock forecasts

    The article, titled "Arcutis Biotherapeutics, Inc. (ARQT) Stock forecasts," appears to be a placeholder or an article where content failed to load. Despite the title...

    Yahoo Finance Singapore•10/12/26•Neutral

    Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts

    Argus has issued a "HOLD" rating for Arcutis Biotherapeutics Inc. (ARQT), lowering its target price to $23.00 from a current price of $26.58. The report provides subratings across various financial aspects including...

    Yahoo! Finance Canada•10/11/26•Somewhat-Bearish

    ARQT Valuation and Fair Value

    P/E
    138.6x
    Forward P/E
    26.4x
    EV/EBITDA
    124.9x
    P/B
    17.2x
    See GNG's fair value

    ARQT Profitability: Margins, ROIC and FCF

    Gross margin
    91.1%
    Operating margin
    12.7%
    Net margin
    6.2%
    ROIC
    8.8%
    ROE
    15.9%
    FCF margin
    8.4%

    ARQT Competitors

    CompanyTicker
    Xenon Pharmaceuticals IncXENE
    Ideaya Biosciences IncIDYA
    Tarsus Pharmaceuticals IncTARS
    Warby Parker IncWRBY
    CareDx IncCDNA
    Celcuity LLCCELC
    Viking Therapeutics IncVKTX
    Enliven Therapeutics Inc.ELVN

    Sector: Healthcare

    ARQT Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    2
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ARQT Bull Case vs Bear Case

    Bull case

    • ARQT beat EPS estimates in 87.5% of its last 8 reported quarters.
    • ARQT grew quarterly revenue 59.3% year over year.
    • 85.7% of ARQT's analyst ratings are Buy or Strong Buy.

    Bear case

    • ARQT trades at 138.6x trailing earnings.

    ARQT Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    37.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.17
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About ARQT

    Does ARQT pay dividends?

    Arcutis Biotherapeutics Inc (ARQT) does not currently pay a regular dividend.

    What is ARQT's P/E ratio?

    Arcutis Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 138.57.

    What is ARQT's market cap?

    Arcutis Biotherapeutics Inc (ARQT) has a market capitalization of $3.32B with a current stock price of $29.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In